Human medicines European public assessment report (EPAR): Xolair, omalizumab, Date of authorisation: 25/10/2005, Revision: 52, Status: Authorised

Nitrosamine impurities: guidance for marketing authorisation holders

Human medicines European public assessment report (EPAR): Sixmo, buprenorphine, Date of authorisation: 19/06/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Cubicin, daptomycin, Date of authorisation: 19/01/2006, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR): Lacosamide Accord, lacosamide, Date of authorisation: 18/09/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Pemetrexed medac, pemetrexed, Date of authorisation: 26/11/2015, Revision: 9, Status: Authorised

Champix

PSUSA/00000210/202408

PSUSA/00001603/202408

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 18, Status: Authorised